drugset / Trial / NCT07484893
A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, pharmacokinetics, and immunogenicity of recombinant human hyaluronidase in healthy Chinese adult male subjects.
Timeline
- Start
- 2026-05-14
- Primary completion
- 2026-08-25
- Completion
- 2026-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rHuPH20 | Protein / enzyme biologic | 5 ml | Subcutaneous |
| Subject | rHuPH20 | Protein / enzyme biologic | 15 ml | Subcutaneous |
| Subject | rHuPH20 | Protein / enzyme biologic | 25 ml | Subcutaneous |
Indications
No indication recorded.